secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001739410-23-000019
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio reveals Phase 1 MAD data for RLYB116: >93% free C5 reduction at 100 mg weekly; cash runway extended to 3Q 2025
--------------------------------------------------------------------------------

- 100 mg weekly dose of RLYB116 achieved >93% mean reduction in free C5 at Day 29; >99% reduction 24h post-first dose.
- RLYB116 half-life >300 hours; low inter-subject variability; all adverse events mild, most common injection-site reaction (60% in 100mg cohort).
- Company deprioritizes Phase 2 start in gMG, focusing on manufacturing to improve tolerability and widen indications.
- Cash runway guidance updated: current resources expected to fund operations into Q3 2025.
- RLYB212 for FNAIT continues as lead program; near-term RLYB116 investments directed to process improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000019/0001739410-23-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941023000019/rlyb-20231220.htm
  HTML page:      https://secwatch.observer/filing/0001739410-23-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer